Please see full Prescribing Information for SHINGRIX. About the NCT05966090 trial The co-administration study is a phase 3, open-label, multi-country study to assess non-inferiority of immune ...
Shingrix pulled in sales of £2 billion (around $2.8 billion) last year from its current indication in the prevention of shingles in the over-50s age group but GSK reckons that younger immune ...
Some results have been hidden because they may be inaccessible to you